Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Aclaris Therapeutics's Enterprise Value is $-33.57 Mil.
Aclaris Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-116.31 Mil. Therefore, Aclaris Therapeutics's EV-to-EBIT ratio for today is 0.29.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Aclaris Therapeutics's Enterprise Value is $-33.57 Mil.
Aclaris Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-115.45 Mil. Therefore, Aclaris Therapeutics's EV-to-EBITDA ratio for today is 0.29.
Aclaris Therapeutics Enterprise Value Historical Data
The historical data trend for Aclaris Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aclaris Therapeutics's Enterprise Value
For the Diagnostics & Research subindustry, Aclaris Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics's Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Enterprise Value falls into.
Aclaris Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Aclaris Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (NAS:ACRS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Aclaris Therapeutics's current Enterprise Value is $-33.57 Mil.
Aclaris Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-116.31 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Aclaris Therapeutics's current Enterprise Value is $-33.57 Mil.
Aclaris Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-115.45 Mil.
Aclaris Therapeutics's current Enterprise Value is $-33.57 Mil.
Aclaris Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Aclaris Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Aclaris Therapeutics (Aclaris Therapeutics) Business Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACRS has been successfully added to your 